Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03271047

Enrollment

Registered

2017-09-01

Start date

2017-10-18

Completion date

2021-02-25

Last updated

2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MSS, RAS-mutant Colorectal Cancer

Keywords

cancer

Brief summary

This is a multicenter, open-label, Phase 1B/2 study to evaluate the safety and assess the preliminary anti-tumor activity of binimetinib administered in combination with nivolumab or nivolumab + ipilimumab in adult patients with advanced metastatic colorectal cancer (mCRC) with microsatellite stable (MSS) disease and presence of a RAS mutation that have received at least one prior line of therapy and no more than 2 prior lines of therapy. The study contains a Phase 1b period to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) and schedule of binimetinib followed by a randomized Phase 2 period to assess the efficacy of the combinations.

Interventions

DRUGbinimetinib

Orally, twice daily.

DRUGnivolumab

Intravenously (IV) every 4 weeks (Q4W)

DRUGipilimumab

intravenously (IV) every 8 weeks (Q8W)

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

In phase 1 it is sequential and then in phase 2 it is parallel.

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Key Inclusion Criteria * Measurable, histologically/cytologically confirmed metastatic colorectal cancer (mCRC). * Able to provide a sufficient amount of representative tumor specimen for central laboratory testing of RAS mutation status and microsatellite stable (MSS). * If a fresh tissue sample is provided, a blood sample is required. * Metastatic colorectal cancer (mCRC) categorized as microsatellite stable (MSS) by polymerase chain reaction (PCR) per local assay at any time prior to Screening or by the central laboratory. * RAS mutation per local assay at any time prior to Screening or by the central laboratory. * Have received at least 1 prior line of therapy and meets at least one of the following criteria: * were unable to tolerate the prior first-line regimen * experienced disease progression during or after prior first-line regimen for metastatic disease * progressed during or within 3 months of completing adjuvant chemotherapy. Note: Generally, treatments that are separated by an event of progression are considered different regimens. * Have received no more than 2 prior lines of therapy (maintenance therapy given in the metastatic setting will not be considered a separate regimen). Generally, treatments that are separated by an event of progression are considered different regimens. * Adequate bone marrow, cardiac, kidney and liver function * Able to take oral medications * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. * Female patients are either postmenopausal for at least 1 year, are surgically sterile for at least 6 weeks, or must agree to take appropriate precautions to avoid pregnancy from screening through follow-up if of child-bearing potential * Non-sterile male patients who are sexually active with female partners of childbearing potential must agree to follow instructions for acceptable or highly effective method(s) of contraception for the duration of study treatment and for 7 months after the last dose of study treatment with nivolumab Key

Exclusion criteria

* Prior treatment with any MEK inhibitor, an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. * Any untreated central nervous system (CNS) lesion. * Patients with an active, known or suspected autoimmune disease. Patients with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. * Known history of retinal vein occlusion (RVO). * Known history of Gilbert's syndrome. * Pregnant or breastfeeding females. * Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \[anti-TNF\] agents) within 2 weeks prior to first day of study treatment: * History of thromboembolic or cerebrovascular events ≤ 6 months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli. * Uncontrolled hypertension defined as persistent systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg despite current therapy. * Concurrent neuromuscular disorder that is associated with the potential of elevated creatine kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy). * History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes). * Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). NOTE: Testing for HIV must be performed at sites where mandated locally. * Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection, and/or detectable virus.

Design outcomes

Primary

Measure	Time frame	Description
Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)	Cycle 1: Day 1 up to Day 28	DLT:Adverse event(AE)/abnormal laboratory assessed unrelated-disease,disease progression,intercurrent illness/concomitant medication/therapies resulting inability tolerate 75% dose intensity in Cycle 1.Total bilirubin(TBL)grade(G)\>=3 (\>3.0\upper limit of normal\[ULN)\]);AST/ALT\>5-8\ULN\>5 days,\>8\ULN,\>3\ULN concurrent TBL\>2\*ULN;G\>=3 serum creatinine,CK elevation,ECG QTcF prolonged,G3 troponin,electrolyte\>72 hours,G3/4 amylase/lipase.G4 ANC,platelet count\>7 days;G3/4 platelet count,other AE except lymphopenia.G\>=3 retinopathy,other disorder\>21 days;G2 uveitis/eye pain/blurred vision/decreased visual acuity;G4 other disorder.Decrease LVEF\>10% G\>=3 cardiac disorders.G3/4 hypertension.G3 fatigue\>=7 days,hypersensitivity,infusion reaction,fever\>=72 hours/hemodynamic compromise,endocrinopathy.G\>=2 interstitial lung disease/pneumonitis;G3 bronchospasm.G3/4 rash,hand foot skin reaction,photosensitivity.G3 colitis;G3/4 diarrhea,nausea/vomiting.Neurologic G3.Other hematologic/nonhematolic G\>=3 AE.
Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1	From start of the treatment until disease progression, death or initiation of new anticancer therapy, whichever occurred first (Phase 2: maximum up to 26 months approximately)	ORR was defined as the percentage of participants who achieved a best overall response (BOR) of complete response (CR) or partial response (PR) as determined by investigator per RECIST v1.1. As per RECIST v1.1, CR was defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures less than (\<)10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference baseline sum of diameters. Non-target lesions must be non-progressive disease (PD). PD was defined as at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was considered progression.

Secondary

Measure	Time frame	Description
Percentage of Participants With Complete Response as Per RECIST v1.1	From start of the treatment until disease progression, death or initiation of new anticancer therapy, whichever occurred first (Phase 1b: maximum up to 9 months approximately and Phase 2: maximum up to 26 months approximately)	Complete response as per RECIST v1.1 was defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm.
Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03	From start of the treatment up to 30 days after last dose or start of new anticancer therapy minus 1 day, whichever occurred first (Phase 1b: maximum up to 9 months approximately and Phase 2: maximum up to 26 months approximately)	AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE: AE resulting in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs: events between first dose of study drug and up to 30 days after last dose or before start of new anticancer therapy minus 1 day, whichever occurred first. TEAE graded by CTCAE grade 4.03: Grade 3: severe/medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care activities of daily living (ADL); Grade 4: life-threatening consequence, urgent intervention indicated. In this outcome measure, number of participants with 'all grades' and 'Grade 3/4' were reported.
Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Phase 1b: Baseline up to 30 days after last dose (maximum up to 9 months approximately), Phase 2: Baseline up to 30 days after last dose (maximum up to 26 months approximately)	Hematological parameters included: Hemoglobin graded high, Hemoglobin graded low, Platelets count graded low, White Blood Cell (WBC) graded high, WBC graded low, Neutrophils graded low, Lymphocytes graded high, Lymphocytes graded low. Coagulation parameters included: International Normalized Ratio (INR) graded high, Activated Partial Thromboplastin Time (aPTT) graded high. Test abnormalities were graded by CTCAE v4.03 as Grade 1=mild; Grade 2=moderate; Grade 3/Grade 4=severe/life-threatening. A grade 0 was assigned for all non-missing values not graded as 1 or higher. If value was graded \>=1 but falls within the normal range, the grade was reset to 0. Categories with at least 1 non-zero data values are reported.
Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Phase 1b: Baseline up to 30 days after last dose (maximum up to 9 months approximately), Phase 2: Baseline up to 30 days after last dose (maximum up to 26 months approximately)	Hematology parameters: Basophils, Eosinophils, Hematocrit, Monocytes, Red blood cells (RBC). Coagulation parameters: Prothrombin Time. Laboratory values were as per laboratory normal ranges. Values above range were reported as high and values below range as low. Laboratory parameters were graded based on laboratory normal ranges as low, normal, high and missing are reported in this outcome measure. Categories with at least 1 non-zero data values are reported.
Phase 1b: Objective Response Rate (ORR) Per RECIST v1.1	From start of the treatment until disease progression, death or initiation of new anticancer therapy, whichever occurred first (Phase 1b: maximum up to 9 months approximately)	ORR was defined as the percentage of participants who achieved a BOR of CR or PR as determined by investigator per RECIST v1.1. As per RECIST v1.1, CR was defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR was defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.
Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Phase 1b: Baseline up to 30 days after last dose (maximum up to 9 months approximately), Phase 2: Baseline up to 30 days after last dose (maximum up to 26 months approximately)	Chemistry laboratory parameters: Blood urea nitrogen (BUN), Total protein, Chloride, Cancer antigen 19-9 (CA 19-9), Brain natriuretic peptide (BNP), Bicarbonate, Direct bilirubin, Carcinoembryonic antigen (CEA), Lactate dehydrogenase (LDH), Uric acid, Troponin I. Thyroid panel laboratory parameters: Thyroid-stimulating hormone (TSH), Free triiodothyronine (T3), Free thyroxine (T4). Laboratory values were as per laboratory normal ranges. Values above range were reported as high and values below range as low. Shift in chemistry and thyroid panel severity from baseline grade low, normal, high and missing to the post baseline grades as low, normal, high and missing are reported in this outcome measure. Categories with at least 1 non-zero data values are reported.
Number of Participants With Abnormal Hepatic Laboratory Values	Phase 1b: Baseline up to 30 days after last dose (maximum up to 9 months approximately), Phase 2: Baseline up to 30 days after last dose (maximum up to 26 months approximately)	Criteria for abnormal hepatic laboratory parameters: Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT): \>3\* upper limit of normal (ULN), \>5\ULN, \>8\ULN, \>10\ULN, \>20\ULN; Total bilirubin (TBL) \>1.5\ULN, \>2\ULN; Alkaline phosphatase (ALP) \>2\ULN, \>3\ULN. Categories with at least 1 non-zero data values are reported.
Concentration Versus Time Summary of Plasma Concentration of Binimetinib	1.5 hours post dose of binimetinib on Day 1, 15 of Cycle 1; pre dose of binimetinib on Day 15 of Cycle 1, 2, 3, 4, 5	—
Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Phase 1b: Baseline up to 30 days after last dose (maximum up to 9 months approximately), Phase 2: Baseline up to 30 days after last dose (maximum up to 26 months approximately)	Abnormalities: Albumin graded low, Alkaline phosphatase (ALP) graded high, Alanine aminotransferase (ALT) graded high, Aspartate aminotransferase (AST) graded high, Bilirubin graded high, Amylase graded high, Creatinine graded high, Corrected calcium graded high, Creatine Kinase (CK) graded high, Glucose graded high, Glucose graded low, Lipase graded high, Magnesium graded high, Magnesium graded low, Potassium graded high, Potassium graded low, Sodium graded high and Sodium graded low. Test abnormalities were graded by CTCAE v4.03 as Grade 1=mild; Grade 2=moderate; Grade 3/Grade 4=severe/life-threatening. A grade 0 was assigned for all non-missing values not graded as 1 or higher. If value was graded \>=1 but falls within the normal range, the grade was reset to 0. Categories with at least 1 non-zero data values are reported.
Duration of Response (DOR) as Per RECIST v1.1	From date of first documented CR/PR to date of first documented PD, death or initiation of new anticancer therapy, whichever occurred first (Phase 1b: maximum up to 9 months approximately, Phase 2: maximum up to 26 months approximately)	DOR was defined as the time between the date of the first documented confirmed response (PR or CR) and the date of the first documented progression or death due to any cause. As per RECIST v1.1: CR was defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes short axis measures \<10 mm. PR was defined as at least 30% decrease in sum of measures (tumor lesions- longest diameter and nodes- short axis) of target lesions, taking as reference baseline sum of diameters. PD was defined as at least 20% increase in sum of diameters of measured lesions taking as references smallest sum of diameters recorded on study (including baseline) and an absolute increase of \>=5 mm or appearance of at least 1 new lesion. Unequivocal progression of existing non-target lesions.

Countries

Belgium, Netherlands, Spain, United Kingdom, United States

Participant flow

Pre-assignment details

This study included 2 phases: Phase 1b and Phase 2. The recommended dose for Phase 2 (RP2D) of binimetinib was determined in Phase 1b (dose finding phase).

Participants by arm

Arm	Count
Phase 1b: Nivolumab+Binimetinib Participants with previously treated MSS metastatic colorectal cancer with RAS mutation received binimetinib at a starting dose of 45 mg tablet orally BID along with 480 mg IV dose of nivolumab every 4 weeks in each 28 day treatment cycle. Binimetinib dose modification to intermitted dosing (3 weeks on treatment and 1 week off treatment) with 45 mg dose or dose reduction to 30 mg BID or 30 mg intermittent dosing based on investigator's decision as per its tolerability among participants. Participants then followed up for safety for around 150 days.	10
Phase 1b: Nivolumab+Ipilimumab+Binimetinib Participants with previously treated MSS metastatic colorectal cancer with RAS mutation received binimetinib at a starting dose of 45 mg tablet BID along with 480 mg IV dose of nivolumab every 4 weeks in each 28 day treatment cycle. Ipilimumab was administered at the dose of 1 mg/kg IV every 8 weeks after completion of nivolumab infusion. Binimetinib dose modification to intermitted dosing (3 weeks on treatment and 1 week off treatment) with 45 mg dose or dose reduction to 30 mg BID or 30 mg intermittent dosing based on investigator's decision as per its tolerability among participants. Participants then followed up for safety for around 150 days.	11
Phase 2: Nivolumab+Binimetinib Participants with previously treated MSS metastatic colorectal cancer with RAS mutation received 45 mg binimetinib tablet orally BID along with 480 mg IV dose of nivolumab every 4 weeks in each 28 day treatment cycle, until disease progression, unacceptable toxicity, withdrawal of informal consent, initiation of subsequent anticancer therapy, lost to follow-up or death. Participants then followed up for safety for around 150 days.	27
Phase 2: Nivolumab+Ipilimumab+Binimetinib Participants with previously treated MSS metastatic colorectal cancer with RAS mutation received 45 mg binimetinib tablet orally BID along with 480 mg IV dose of nivolumab every 4 weeks in each 28 day treatment cycle. Ipilimumab was administered at the dose of 1 mg/kg IV every 8 weeks after completion of nivolumab infusion until disease progression, unacceptable toxicity, withdrawal of informal consent, initiation of subsequent anticancer therapy, lost to follow-up or death. Participants then followed up for safety for around 150 days.	27
Total	75

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003
Phase 1b: Dose Finding Period	Completed follow-up per protocol	1	1	0	0
Phase 1b: Dose Finding Period	Death	8	8	0	0
Phase 1b: Dose Finding Period	Lost to Follow-up	1	0	0	0
Phase 1b: Dose Finding Period	Withdrawal by Subject	0	2	0	0
Randomized Phase 2 Period	Completed follow-up per protocol	0	0	0	4
Randomized Phase 2 Period	Death	0	0	20	21
Randomized Phase 2 Period	Lost to Follow-up	0	0	2	1
Randomized Phase 2 Period	Other	0	0	0	1
Randomized Phase 2 Period	Withdrawal by Subject	0	0	5	0

Baseline characteristics

Characteristic	Phase 1b: Nivolumab+Binimetinib	Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Phase 2: Nivolumab+Binimetinib	Phase 2: Nivolumab+Ipilimumab+Binimetinib	Total
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	5 Participants	2 Participants	8 Participants	7 Participants	22 Participants
Age, Categorical Between 18 and 65 years	5 Participants	9 Participants	19 Participants	20 Participants	53 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	10 Participants	11 Participants	21 Participants	23 Participants	65 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	5 Participants	4 Participants	9 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants
Race (NIH/OMB) Black or African American	1 Participants	0 Participants	1 Participants	1 Participants	3 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	4 Participants	3 Participants	7 Participants
Race (NIH/OMB) White	9 Participants	11 Participants	21 Participants	23 Participants	64 Participants
Sex: Female, Male Female	2 Participants	4 Participants	11 Participants	10 Participants	27 Participants
Sex: Female, Male Male	8 Participants	7 Participants	16 Participants	17 Participants	48 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	8 / 10	8 / 11	20 / 27	21 / 27
other Total, other adverse events	10 / 10	11 / 11	27 / 27	27 / 27
serious Total, serious adverse events	5 / 10	6 / 11	12 / 27	11 / 27

Outcome results

Primary

Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)

DLT:Adverse event(AE)/abnormal laboratory assessed unrelated-disease,disease progression,intercurrent illness/concomitant medication/therapies resulting inability tolerate 75% dose intensity in Cycle 1.Total bilirubin(TBL)grade(G)\>=3 (\>3.0\*upper limit of normal\[ULN)\]);AST/ALT\>5-8\*ULN\>5 days,\>8\*ULN,\>3\*ULN concurrent TBL\>2\*ULN;G\>=3 serum creatinine,CK elevation,ECG QTcF prolonged,G3 troponin,electrolyte\>72 hours,G3/4 amylase/lipase.G4 ANC,platelet count\>7 days;G3/4 platelet count,other AE except lymphopenia.G\>=3 retinopathy,other disorder\>21 days;G2 uveitis/eye pain/blurred vision/decreased visual acuity;G4 other disorder.Decrease LVEF\>10% G\>=3 cardiac disorders.G3/4 hypertension.G3 fatigue\>=7 days,hypersensitivity,infusion reaction,fever\>=72 hours/hemodynamic compromise,endocrinopathy.G\>=2 interstitial lung disease/pneumonitis;G3 bronchospasm.G3/4 rash,hand foot skin reaction,photosensitivity.G3 colitis;G3/4 diarrhea,nausea/vomiting.Neurologic G3.Other hematologic/nonhematolic G\>=3 AE.

Time frame: Cycle 1: Day 1 up to Day 28

Population: Dose-Determining Set (DDS) included all participants in Phase 1b who experienced a DLT or receive at least 75% of the planned binimetinib dose intensity during Cycle 1.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Phase 1b: Nivolumab+Binimetinib	Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)	2 Participants

Primary

Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1

ORR was defined as the percentage of participants who achieved a best overall response (BOR) of complete response (CR) or partial response (PR) as determined by investigator per RECIST v1.1. As per RECIST v1.1, CR was defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures less than (\<)10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference baseline sum of diameters. Non-target lesions must be non-progressive disease (PD). PD was defined as at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was considered progression.

Time frame: From start of the treatment until disease progression, death or initiation of new anticancer therapy, whichever occurred first (Phase 2: maximum up to 26 months approximately)

Population: All participants randomized to study treatment in Phase 2.

Arm	Measure	Value (NUMBER)
Phase 1b: Nivolumab+Binimetinib	Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1	0.0 Percentage of participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1	7.4 Percentage of participants

Secondary

Concentration Versus Time Summary of Plasma Concentration of Binimetinib

Time frame: 1.5 hours post dose of binimetinib on Day 1, 15 of Cycle 1; pre dose of binimetinib on Day 15 of Cycle 1, 2, 3, 4, 5

Population: The pharmacokinetic analysis set included of all participants who received at least 1 dose of binimetinib and have at least one evaluable bioanalytical result. Here Number Analyzed signifies number of participants evaluable for specified rows.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Phase 1b: Nivolumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 1 Day 1: 1.5 Hours post dose	228 nanogram per milliliter	Geometric Coefficient of Variation 152.2
Phase 1b: Nivolumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 1 Day 15: 1.5 Hours post dose	542 nanogram per milliliter	Geometric Coefficient of Variation 57.6
Phase 1b: Nivolumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 4 Day 15: pre dose	NA nanogram per milliliter	—
Phase 1b: Nivolumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 2 Day 15: pre dose	108 nanogram per milliliter	Geometric Coefficient of Variation 52.9
Phase 1b: Nivolumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 1 Day 15: pre dose	135 nanogram per milliliter	Geometric Coefficient of Variation 60.9
Phase 1b: Nivolumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 5 Day 15: pre dose	NA nanogram per milliliter	—
Phase 1b: Nivolumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 3 Day 15: pre dose	140 nanogram per milliliter	Geometric Coefficient of Variation 42
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 2 Day 15: pre dose	NA nanogram per milliliter	—
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 1 Day 1: 1.5 Hours post dose	163 nanogram per milliliter	Geometric Coefficient of Variation 129.6
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 1 Day 15: pre dose	125 nanogram per milliliter	Geometric Coefficient of Variation 103.9
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 1 Day 15: 1.5 Hours post dose	414 nanogram per milliliter	Geometric Coefficient of Variation 24.5
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 3 Day 15: pre dose	NA nanogram per milliliter	—
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 4 Day 15: pre dose	NA nanogram per milliliter	—
Phase 2: Nivolumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 1 Day 15: pre dose	77.0 nanogram per milliliter	Geometric Coefficient of Variation 141.2
Phase 2: Nivolumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 5 Day 15: pre dose	NA nanogram per milliliter	—
Phase 2: Nivolumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 4 Day 15: pre dose	NA nanogram per milliliter	—
Phase 2: Nivolumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 3 Day 15: pre dose	NA nanogram per milliliter	—
Phase 2: Nivolumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 1 Day 1: 1.5 Hours post dose	261 nanogram per milliliter	Geometric Coefficient of Variation 90.9
Phase 2: Nivolumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 2 Day 15: pre dose	88.5 nanogram per milliliter	Geometric Coefficient of Variation 111.3
Phase 2: Nivolumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 1 Day 15: 1.5 Hours post dose	294 nanogram per milliliter	Geometric Coefficient of Variation 84.4
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 1 Day 1: 1.5 Hours post dose	217 nanogram per milliliter	Geometric Coefficient of Variation 134.5
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 2 Day 15: pre dose	120 nanogram per milliliter	Geometric Coefficient of Variation 77.7
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 3 Day 15: pre dose	89.2 nanogram per milliliter	Geometric Coefficient of Variation 183.4
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 1 Day 15: pre dose	81.8 nanogram per milliliter	Geometric Coefficient of Variation 143.6
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 5 Day 15: pre dose	NA nanogram per milliliter	—
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 4 Day 15: pre dose	NA nanogram per milliliter	—
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Concentration Versus Time Summary of Plasma Concentration of Binimetinib	Cycle 1 Day 15: 1.5 Hours post dose	324 nanogram per milliliter	Geometric Coefficient of Variation 83.3

Secondary

Duration of Response (DOR) as Per RECIST v1.1

DOR was defined as the time between the date of the first documented confirmed response (PR or CR) and the date of the first documented progression or death due to any cause. As per RECIST v1.1: CR was defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes short axis measures \<10 mm. PR was defined as at least 30% decrease in sum of measures (tumor lesions- longest diameter and nodes- short axis) of target lesions, taking as reference baseline sum of diameters. PD was defined as at least 20% increase in sum of diameters of measured lesions taking as references smallest sum of diameters recorded on study (including baseline) and an absolute increase of \>=5 mm or appearance of at least 1 new lesion. Unequivocal progression of existing non-target lesions.

Time frame: From date of first documented CR/PR to date of first documented PD, death or initiation of new anticancer therapy, whichever occurred first (Phase 1b: maximum up to 9 months approximately, Phase 2: maximum up to 26 months approximately)

Population: FAS included all participants who received at least 1 dose of any study drug in Phase 1b and all participants randomized to study treatment in Phase 2. Here, Overall Number of Participants Analyzed signifies number of participants who achieved an objective response. There were no participants who had event in Phase 1b and Nivolumab and Binimetinib group of Phase 2.

Arm	Measure	Value (MEDIAN)
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Duration of Response (DOR) as Per RECIST v1.1	11.4 Months

Secondary

Number of Participants With Abnormal Hepatic Laboratory Values

Criteria for abnormal hepatic laboratory parameters: Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT): \>3\* upper limit of normal (ULN), \>5\*ULN, \>8\*ULN, \>10\*ULN, \>20\*ULN; Total bilirubin (TBL) \>1.5\*ULN, \>2\*ULN; Alkaline phosphatase (ALP) \>2\*ULN, \>3\*ULN. Categories with at least 1 non-zero data values are reported.

Time frame: Phase 1b: Baseline up to 30 days after last dose (maximum up to 9 months approximately), Phase 2: Baseline up to 30 days after last dose (maximum up to 26 months approximately)

Population: Safety set included of all participants who received at least 1 dose of study drug. Here Number Analyzed signifies number of participants evaluable for specified rows.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	Total bilirubin: >1.5 ULN	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	Alkaline phosphatase: >3 ULN	4 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT or AST: >5 ULN	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT: >3 ULN	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT or AST: >8 ULN	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT: >8 ULN	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	AST: >3 ULN	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT: >5 ULN	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	Alkaline phosphatase: >2 ULN	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	AST: >5 ULN	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	AST: >8 ULN	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT or AST: >3 ULN	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT: >5 ULN	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT or AST: >3 ULN	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	AST: >3 ULN	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT or AST: >8 ULN	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	Total bilirubin: >1.5 ULN	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT or AST: >5 ULN	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT: >3 ULN	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	AST: >8 ULN	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	AST: >5 ULN	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT: >8 ULN	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	Alkaline phosphatase: >3 ULN	4 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	Alkaline phosphatase: >2 ULN	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT or AST: >5 ULN	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT: >3 ULN	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT: >5 ULN	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT: >8 ULN	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	AST: >3 ULN	4 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	AST: >5 ULN	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	AST: >8 ULN	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT or AST: >3 ULN	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT or AST: >8 ULN	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	Total bilirubin: >1.5 ULN	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	Alkaline phosphatase: >2 ULN	4 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	Alkaline phosphatase: >3 ULN	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	AST: >8 ULN	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	AST: >5 ULN	3 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT: >3 ULN	7 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	Total bilirubin: >1.5 ULN	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	AST: >3 ULN	8 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT: >8 ULN	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	Alkaline phosphatase: >3 ULN	4 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	Alkaline phosphatase: >2 ULN	8 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT or AST: >5 ULN	4 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT or AST: >3 ULN	7 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT: >5 ULN	5 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Abnormal Hepatic Laboratory Values	ALT or AST: >8 ULN	1 Participants

Secondary

Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation

Hematological parameters included: Hemoglobin graded high, Hemoglobin graded low, Platelets count graded low, White Blood Cell (WBC) graded high, WBC graded low, Neutrophils graded low, Lymphocytes graded high, Lymphocytes graded low. Coagulation parameters included: International Normalized Ratio (INR) graded high, Activated Partial Thromboplastin Time (aPTT) graded high. Test abnormalities were graded by CTCAE v4.03 as Grade 1=mild; Grade 2=moderate; Grade 3/Grade 4=severe/life-threatening. A grade 0 was assigned for all non-missing values not graded as 1 or higher. If value was graded \>=1 but falls within the normal range, the grade was reset to 0. Categories with at least 1 non-zero data values are reported.

Time frame: Phase 1b: Baseline up to 30 days after last dose (maximum up to 9 months approximately), Phase 2: Baseline up to 30 days after last dose (maximum up to 26 months approximately)

Population: Safety set included of all participants who received at least 1 dose of study drug. Here Number Analyzed signifies number of participants evaluable for specified rows.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 3 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	8 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 2 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 2 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 2 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 3 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 3 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	9 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	4 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	9 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	5 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 1 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	9 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	10 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	6 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes - CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	6 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	10 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 3 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 1 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	8 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 2 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	11 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 1 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	11 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 1 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 1 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	11 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 1 (at post baseline)	4 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	11 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	9 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 1 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	11 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 3 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes - CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	7 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 3 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 1 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 1 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	3 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	6 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 1 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 3 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	25 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	23 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 1 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 1 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	21 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	4 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	6 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 1 (at post baseline)	4 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 2 (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 2 (at baseline) to Grade 2 (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 2 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	26 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes - CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	11 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	4 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 1 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 1 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 1 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 2 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 2 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 2 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 3 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 1 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	21 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Grade 4 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 3 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	26 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	16 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	6 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 1 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	16 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	4 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	5 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 1 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Missing (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 1 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	4 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 1 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	4 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes - CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	11 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	27 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	26 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 2 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 1 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	17 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 2 (at baseline) to Grade 2 (at post baseline)	5 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	6 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 1 (at post baseline)	4 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Neutrophils- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	26 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	26 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	8 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Grade 1 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	aPTT- CTCAE Graded High: Missing (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 1 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	10 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 2 (at baseline) to Grade 3 (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Hemoglobin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	5 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	24 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 2 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 2 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 1 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 1 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	INR- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	13 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 1 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	4 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	WBC- CTCAE Graded Low: Grade 0 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Lymphocytes- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	6 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation	Platelets- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	22 Participants

Secondary

Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry

Abnormalities: Albumin graded low, Alkaline phosphatase (ALP) graded high, Alanine aminotransferase (ALT) graded high, Aspartate aminotransferase (AST) graded high, Bilirubin graded high, Amylase graded high, Creatinine graded high, Corrected calcium graded high, Creatine Kinase (CK) graded high, Glucose graded high, Glucose graded low, Lipase graded high, Magnesium graded high, Magnesium graded low, Potassium graded high, Potassium graded low, Sodium graded high and Sodium graded low. Test abnormalities were graded by CTCAE v4.03 as Grade 1=mild; Grade 2=moderate; Grade 3/Grade 4=severe/life-threatening. A grade 0 was assigned for all non-missing values not graded as 1 or higher. If value was graded \>=1 but falls within the normal range, the grade was reset to 0. Categories with at least 1 non-zero data values are reported.

Time frame: Phase 1b: Baseline up to 30 days after last dose (maximum up to 9 months approximately), Phase 2: Baseline up to 30 days after last dose (maximum up to 26 months approximately)

Population: Safety set included of all participants who received at least 1 dose of study drug. Here Number Analyzed signifies number of participants evaluable for specified rows.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	7 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	9 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	5 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose - CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	7 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 2 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	7 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 2 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	4 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 3 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	10 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	8 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Missing (at baseline) to Missing (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 1 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	5 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	4 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 1 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Bilirubin- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	10 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	9 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Bilirubin- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Bilirubin- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	8 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Missing (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 2 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	7 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	10 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	10 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 2 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	10 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	5 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Missing (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	4 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	5 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	7 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	4 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 1 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	6 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	7 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Missing (at baseline) to Missing (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Missing (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	10 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Missing (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose - CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	4 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	6 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	5 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	11 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	10 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	4 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 2 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 3 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Bilirubin- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	9 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	4 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 2 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 2 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 3 (at baseline) to Grade 3 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	11 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 3 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	7 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Bilirubin- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	9 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Bilirubin- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	10 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Bilirubin- CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	11 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	3 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	11 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	3 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	12 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	7 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 2 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 2 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 3 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	8 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	11 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 2 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	8 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	9 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	7 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	7 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	8 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	5 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 2 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 2 (at baseline) to Grade 3 (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 3 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 3 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	18 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	5 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Bilirubin- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	25 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Bilirubin- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Bilirubin- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Bilirubin- CTCAE Graded High: Grade 4 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	24 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	25 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	11 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	6 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	5 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 4 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	6 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	14 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	5 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Grade 4 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	23 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 1 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	18 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose - CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	5 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose - CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 3 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 3 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 3 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Missing (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Missing (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Missing (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	17 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	4 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	22 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 2 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	26 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	20 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 4 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 3 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	23 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	19 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 4 (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 1 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	23 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	13 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	3 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	8 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	7 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	7 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 4 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	5 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded Low: Grade 1 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	22 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	23 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	25 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 2 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 4 (at baseline) to Grade 4 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Bilirubin- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Bilirubin- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 2 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	24 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Bilirubin- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	24 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 2 (at baseline) to Grade 4 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	12 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Amylase- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	20 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 3 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 3 (at baseline) to Grade 3 (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Corrected Calcium- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	25 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	27 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 2 (at baseline) to Grade 3 (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 2 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Magnesium- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	7 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	23 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	6 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	4 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 4 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	6 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	11 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Sodium- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	5 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	14 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 1 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	3 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 1 (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Albumin- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	8 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose - CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	5 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	3 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 1 (at baseline) to Grade 0 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	23 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose - CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	3 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 3 (at baseline) to Grade 2 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 1 (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 3 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Grade 3 (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 0 (at baseline) to Grade 1 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded Low: Grade 0 (at baseline) to Grade 0 (at post baseline)	26 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	4 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Missing (at baseline) to Grade 0 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase - CTCAE Graded High: Missing (at baseline) to Grade 1 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 0 (at baseline) to Grade 3 (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Missing (at baseline) to Grade 3 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Grade 4 (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	AST- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Glucose- CTCAE Graded High: Missing (at baseline) to Missing (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	18 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatinine- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	7 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	ALT- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	5 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 0 (at post baseline)	15 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 1 (at baseline) to Grade 4 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 1 (at baseline) to Grade 3 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Potassium- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	4 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 1 (at baseline) to Grade 2 (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Creatine kinase- CTCAE Graded High: Grade 0 (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Alkaline phosphatase- CTCAE Graded High: Grade 0 (at baseline) to Grade 1 (at post baseline)	5 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry	Lipase- CTCAE Graded High: Grade 0 (at baseline) to Grade 2 (at post baseline)	0 Participants

Secondary

Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function

Chemistry laboratory parameters: Blood urea nitrogen (BUN), Total protein, Chloride, Cancer antigen 19-9 (CA 19-9), Brain natriuretic peptide (BNP), Bicarbonate, Direct bilirubin, Carcinoembryonic antigen (CEA), Lactate dehydrogenase (LDH), Uric acid, Troponin I. Thyroid panel laboratory parameters: Thyroid-stimulating hormone (TSH), Free triiodothyronine (T3), Free thyroxine (T4). Laboratory values were as per laboratory normal ranges. Values above range were reported as high and values below range as low. Shift in chemistry and thyroid panel severity from baseline grade low, normal, high and missing to the post baseline grades as low, normal, high and missing are reported in this outcome measure. Categories with at least 1 non-zero data values are reported.

Time frame: Phase 1b: Baseline up to 30 days after last dose (maximum up to 9 months approximately), Phase 2: Baseline up to 30 days after last dose (maximum up to 26 months approximately)

Population: Safety set included of all participants who received at least 1 dose of study drug. Here Number Analyzed signifies number of participants evaluable for specified rows.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Normal (at baseline) to Low (at post baseline)	2 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN: High (at baseline) to High (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: High (at baseline) to High (at post baseline)	9 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to High and Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: Normal (at baseline) to Normal (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to Low (at post baseline)	2 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: High (at baseline) to High (at post baseline)	7 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to Normal (at post baseline)	7 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Troponin I: Missing (at baseline) to Normal (at post baseline)	4 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to High (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: Normal (at baseline) to Normal (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to High and Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to Normal (at post baseline)	5 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to Low (at post baseline)	5 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: High (at baseline) to High (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: High (at baseline) to High (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: Normal (at baseline) to Normal (at post baseline)	8 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Troponin I: Missing (at baseline) to High (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: Normal (at baseline) to High (at post baseline)	5 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: Normal (at baseline) to Normal (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: Normal (at baseline) to High (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to High and Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: Low (at baseline) to Low (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to High (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to High and Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Normal (at baseline) to Low (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to Normal (at post baseline)	10 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: High (at baseline) to High (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN: Normal (at baseline) to Normal (at post baseline)	4 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to Normal (at post baseline)	8 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Normal (at baseline) to High and Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN (mmol/L): Normal (at baseline) to High (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Normal (at baseline) to Normal (at post baseline)	7 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Normal (at baseline) to Low (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Normal (at baseline) to Normal (at post baseline)	8 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Normal (at baseline) to High & Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: High (at baseline) to High (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Normal (at baseline) to Normal (at post baseline)	8 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Low (at baseline) to High (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Troponin I: Missing (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Low (at baseline) to Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Low (at baseline) to Normal (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Low (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Normal (at baseline) to Low (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Normal (at baseline) to Normal (at post baseline)	5 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Normal (at baseline) to High (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: High (at baseline) to High (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: Normal (at baseline) to Normal (at post baseline)	6 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: Normal (at baseline) to High (at post baseline)	3 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: High (at baseline) to Normal (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: High (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN: Normal (at baseline) to Normal (at post baseline)	3 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN (mmol/L): Normal (at baseline) to High (at post baseline)	5 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN: High (at baseline) to High (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Low (at baseline) to Normal (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to Low (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to Normal (at post baseline)	6 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to High (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to High and Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: Normal (at baseline) to Normal (at post baseline)	3 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: High (at baseline) to High (at post baseline)	6 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: High (at baseline) to Missing (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: High (at baseline) to High (at post baseline)	9 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: High (at baseline) to Missing (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Low (at baseline) to Low (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Low (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Normal (at baseline) to Low (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Normal (at baseline) to Normal (at post baseline)	7 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Normal (at baseline) to High & Low (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Normal (at baseline) to Low (at post baseline)	5 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Normal (at baseline) to Normal (at post baseline)	5 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Normal (at baseline) to High and Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Low (at baseline) to Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Low (at baseline) to Normal (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to Low (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to Normal (at post baseline)	8 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to High and Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: Normal (at baseline) to Normal (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: Normal (at baseline) to High (at post baseline)	4 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: High (at baseline) to High (at post baseline)	6 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Low (at baseline) to Low (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to Low (at post baseline)	6 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to Normal (at post baseline)	4 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to High and Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to Normal (at post baseline)	7 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to High and Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: High (at baseline) to Normal (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: High (at baseline) to High (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: High (at baseline) to Missing (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Troponin I: Normal (at baseline) to Normal (at post baseline)	2 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Troponin I: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Troponin I: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Troponin I: Missing (at baseline) to Normal (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: High (at baseline) to Missing (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Low (at baseline) to Low (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Low (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to Low (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Normal (at baseline) to Low (at post baseline)	8 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN: High (at baseline) to Normal (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Normal (at baseline) to Normal (at post baseline)	15 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Normal (at baseline) to Low (at post baseline)	4 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Normal (at baseline) to High (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Troponin I: Normal (at baseline) to Missing (at post baseline)	14 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Normal (at baseline) to High & Low (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Low (at baseline) to Low (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Low (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to Normal (at post baseline)	14 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Normal (at baseline) to Low (at post baseline)	8 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN (mmol/L): Normal (at baseline) to High (at post baseline)	9 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Normal (at baseline) to Normal (at post baseline)	15 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Normal (at baseline) to High and Low (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN: Normal (at baseline) to Normal (at post baseline)	15 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Troponin I: Normal (at baseline) to Normal (at post baseline)	11 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Normal (at baseline) to Missing (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to High (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Low (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to Low (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to Normal (at post baseline)	17 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to High and Low (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to High (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to High and Low (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to Missing (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: High (at baseline) to Low (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: High (at baseline) to Normal (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: Normal (at baseline) to High (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: Normal (at baseline) to Normal (at post baseline)	6 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: Normal (at baseline) to Normal (at post baseline)	24 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to Missing (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: Normal (at baseline) to High (at post baseline)	14 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: High (at baseline) to High (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Low (at baseline) to Normal (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: High (at baseline) to High (at post baseline)	6 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Troponin I: Normal (at baseline) to High (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: High (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: High (at baseline) to Normal (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: High (at baseline) to Normal (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to Low (at post baseline)	11 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to Normal (at post baseline)	12 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Normal (at baseline) to High (at post baseline)	4 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: High (at baseline) to High (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to High and Low (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to High (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: Normal (at baseline) to Normal (at post baseline)	6 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Low (at baseline) to Low (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: Normal (at baseline) to High (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to Normal (at post baseline)	18 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to High and Low (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: High (at baseline) to Normal (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to Low (at post baseline)	6 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Normal (at baseline) to Normal (at post baseline)	15 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: High (at baseline) to High (at post baseline)	16 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: High (at baseline) to Missing (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Low (at baseline) to High (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: Normal (at baseline) to Normal (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: Normal (at baseline) to High (at post baseline)	2 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Low (at baseline) to Normal (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: High (at baseline) to Normal (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: High (at baseline) to High (at post baseline)	20 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN: High (at baseline) to High (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to Normal (at post baseline)	11 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: Normal (at baseline) to Normal (at post baseline)	5 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: Normal (at baseline) to Normal (at post baseline)	3 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: Normal (at baseline) to High (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: Normal (at baseline) to High (at post baseline)	10 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Normal (at baseline) to Low (at post baseline)	4 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: High (at baseline) to High (at post baseline)	3 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Low (at baseline) to Low (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to Missing (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Troponin I: Missing (at baseline) to Normal (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Low (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN: High (at baseline) to Normal (at post baseline)	3 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: High (at baseline) to Normal (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN: High (at baseline) to High (at post baseline)	3 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Normal (at baseline) to Low (at post baseline)	3 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: Normal (at baseline) to High (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to Low (at post baseline)	3 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Normal (at baseline) to Normal (at post baseline)	22 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: High (at baseline) to High (at post baseline)	11 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Normal (at baseline) to High (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to Low (at post baseline)	9 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to High and Low (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	LDH: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Chloride: Normal (at baseline) to High & Low (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Low (at baseline) to Normal (at post baseline)	3 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Low (at baseline) to Low (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: High (at baseline) to Normal (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Low (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN (mmol/L): Normal (at baseline) to High (at post baseline)	7 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Low (at baseline) to Low (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Normal (at baseline) to Low (at post baseline)	7 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to Low (at post baseline)	11 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to Normal (at post baseline)	20 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Normal (at baseline) to High (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Normal (at baseline) to Normal (at post baseline)	15 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BUN: Normal (at baseline) to Normal (at post baseline)	14 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Low (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Troponin I: Normal (at baseline) to High (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Normal (at baseline) to High and Low (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to Normal (at post baseline)	14 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Low (at baseline) to Low (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T3: High (at baseline) to High (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: High (at baseline) to High (at post baseline)	16 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Low (at baseline) to Low (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to High (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Low (at baseline) to Normal (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: High (at baseline) to High (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Low (at baseline) to High (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Troponin I: Missing (at baseline) to High (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to Low (at post baseline)	3 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Troponin I: Normal (at baseline) to Normal (at post baseline)	10 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to High and Low (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to Normal (at post baseline)	17 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to High (at post baseline)	3 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Protein: Normal (at baseline) to High (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to High (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: High (at baseline) to High (at post baseline)	20 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	TSH: Normal (at baseline) to High and Low (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Bicarbonate: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to High and Low (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: Normal (at baseline) to High (at post baseline)	3 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Low (at baseline) to Normal (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: High (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: Normal (at baseline) to Missing (at post baseline)	2 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Uric acid: Normal (at baseline) to Normal (at post baseline)	16 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: High (at baseline) to Low (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CEA: High (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Free T4: High (at baseline) to Normal (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	CA 19-9: Normal (at baseline) to Normal (at post baseline)	7 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	BNP: Normal (at baseline) to Normal (at post baseline)	22 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function	Troponin I: Normal (at baseline) to Missing (at post baseline)	14 Participants

Secondary

Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation

Hematology parameters: Basophils, Eosinophils, Hematocrit, Monocytes, Red blood cells (RBC). Coagulation parameters: Prothrombin Time. Laboratory values were as per laboratory normal ranges. Values above range were reported as high and values below range as low. Laboratory parameters were graded based on laboratory normal ranges as low, normal, high and missing are reported in this outcome measure. Categories with at least 1 non-zero data values are reported.

Time frame: Phase 1b: Baseline up to 30 days after last dose (maximum up to 9 months approximately), Phase 2: Baseline up to 30 days after last dose (maximum up to 26 months approximately)

Population: Safety set included of all participants who received at least 1 dose of study drug. Here Number Analyzed signifies number of participants evaluable for specified rows.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: High (at baseline) to High (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Monocytes: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Eosinophils: Normal (at baseline) to Normal (at post baseline)	7 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Monocytes: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Low (at baseline) to Low (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Normal (at baseline) to Normal (at post baseline)	2 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Low (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Normal (at baseline) to Low (at post baseline)	6 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Eosinophils: Normal (at baseline) to High (at post baseline)	2 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Eosinophils: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Basophils: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Eosinophils: High (at baseline) to Normal (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Low (at baseline) to Low (at post baseline)	2 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Basophils: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Low (at baseline) to Normal (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: Normal (at baseline) to High (at post baseline)	4 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Low (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Normal (at baseline) to Low (at post baseline)	5 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: Normal (at baseline) to Normal (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Normal (at baseline) to Normal (at post baseline)	3 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Eosinophils: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: High (at baseline) to Normal (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Normal (at baseline) to High & Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: High (at baseline) to Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Monocytes: Normal (at baseline) to Low (at post baseline)	1 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Basophils: Normal (at baseline) to Normal (at post baseline)	10 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Monocytes: Normal (at baseline) to Normal (at post baseline)	9 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Monocytes: Normal (at baseline) to High (at post baseline)	4 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Eosinophils: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: Normal (at baseline) to High (at post baseline)	4 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Monocytes: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Eosinophils: Normal (at baseline) to Normal (at post baseline)	11 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Normal (at baseline) to Normal (at post baseline)	4 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Normal (at baseline) to Normal (at post baseline)	4 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Low (at baseline) to Normal (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Low (at baseline) to Low (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Basophils: Normal (at baseline) to Normal (at post baseline)	11 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Basophils: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Monocytes: Normal (at baseline) to Normal (at post baseline)	7 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Low (at baseline) to Normal (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: High (at baseline) to Normal (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Normal (at baseline) to Low (at post baseline)	5 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Low (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Eosinophils: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Basophils: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: Normal (at baseline) to Normal (at post baseline)	3 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Eosinophils: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Monocytes: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Normal (at baseline) to Low (at post baseline)	4 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: High (at baseline) to High (at post baseline)	3 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Normal (at baseline) to High & Low (at post baseline)	1 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Low (at baseline) to Low (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: Normal (at baseline) to High (at post baseline)	11 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Basophils: Normal (at baseline) to Low (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Basophils: Normal (at baseline) to Normal (at post baseline)	25 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Basophils: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Eosinophils: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Eosinophils: Normal (at baseline) to Normal (at post baseline)	25 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Eosinophils: Normal (at baseline) to High (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Eosinophils: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Low (at baseline) to Low (at post baseline)	8 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Low (at baseline) to Normal (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Low (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Normal (at baseline) to Low (at post baseline)	13 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Normal (at baseline) to Normal (at post baseline)	4 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Normal (at baseline) to High & Low (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Monocytes: Normal (at baseline) to Low (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Monocytes: Normal (at baseline) to Normal (at post baseline)	19 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Monocytes: Normal (at baseline) to High (at post baseline)	6 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Monocytes: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Low (at baseline) to Low (at post baseline)	13 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Low (at baseline) to Normal (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Normal (at baseline) to Low (at post baseline)	8 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Normal (at baseline) to Normal (at post baseline)	3 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Normal (at baseline) to High (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Normal (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: Normal (at baseline) to Normal (at post baseline)	8 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: High (at baseline) to High (at post baseline)	7 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: High (at baseline) to Missing (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Monocytes: Normal (at baseline) to High (at post baseline)	6 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: High (at baseline) to High (at post baseline)	9 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Normal (at baseline) to High (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Monocytes: Normal (at baseline) to Normal (at post baseline)	20 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Monocytes: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Basophils: Normal (at baseline) to Normal (at post baseline)	27 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Normal (at baseline) to High & Low (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: High (at baseline) to Low (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Normal (at baseline) to Normal (at post baseline)	6 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Normal (at baseline) to Low (at post baseline)	12 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Low (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Basophils: Normal (at baseline) to Low (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: Normal (at baseline) to Normal (at post baseline)	8 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Low (at baseline) to Normal (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Hematocrit: Low (at baseline) to Low (at post baseline)	9 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Eosinophils: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: Normal (at baseline) to High (at post baseline)	9 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Eosinophils: Normal (at baseline) to High (at post baseline)	6 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Eosinophils: Normal (at baseline) to Normal (at post baseline)	20 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: Missing (at baseline) to High (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: High (at baseline) to Normal (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Eosinophils: Normal (at baseline) to Low (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Low (at baseline) to Normal (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Basophils: Normal (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Normal (at baseline) to Low (at post baseline)	10 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Low (at baseline) to Low (at post baseline)	6 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Monocytes: High (at baseline) to Normal (at post baseline)	1 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Prothrombin Time: High (at baseline) to Missing (at post baseline)	0 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	RBC: Normal (at baseline) to Normal (at post baseline)	9 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation	Monocytes: Normal (at baseline) to Missing (at post baseline)	0 Participants

Secondary

Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03

AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE: AE resulting in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs: events between first dose of study drug and up to 30 days after last dose or before start of new anticancer therapy minus 1 day, whichever occurred first. TEAE graded by CTCAE grade 4.03: Grade 3: severe/medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care activities of daily living (ADL); Grade 4: life-threatening consequence, urgent intervention indicated. In this outcome measure, number of participants with 'all grades' and 'Grade 3/4' were reported.

Time frame: From start of the treatment up to 30 days after last dose or start of new anticancer therapy minus 1 day, whichever occurred first (Phase 1b: maximum up to 9 months approximately and Phase 2: maximum up to 26 months approximately)

Population: The safety set included of all participants who received at least 1 dose of study drug.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03	Treatment emergent AEs- All grades	10 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03	Treatment emergent SAEs- All grades	5 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03	Treatment emergent AEs- Grade 3/4	6 Participants
Phase 1b: Nivolumab+Binimetinib	Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03	Treatment emergent SAEs- Grade 3/4	5 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03	Treatment emergent SAEs- All grades	6 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03	Treatment emergent AEs- Grade 3/4	8 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03	Treatment emergent SAEs- Grade 3/4	6 Participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03	Treatment emergent AEs- All grades	11 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03	Treatment emergent AEs- Grade 3/4	19 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03	Treatment emergent SAEs- All grades	12 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03	Treatment emergent SAEs- Grade 3/4	11 Participants
Phase 2: Nivolumab+Binimetinib	Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03	Treatment emergent AEs- All grades	27 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03	Treatment emergent SAEs- Grade 3/4	10 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03	Treatment emergent SAEs- All grades	11 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03	Treatment emergent AEs- All grades	27 Participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03	Treatment emergent AEs- Grade 3/4	21 Participants

Secondary

Percentage of Participants With Complete Response as Per RECIST v1.1

Complete response as per RECIST v1.1 was defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm.

Time frame: From start of the treatment until disease progression, death or initiation of new anticancer therapy, whichever occurred first (Phase 1b: maximum up to 9 months approximately and Phase 2: maximum up to 26 months approximately)

Population: FAS included all participants who received at least 1 dose of any study drug in Phase 1b and all participants randomized to study treatment in Phase 2.

Arm	Measure	Value (NUMBER)
Phase 1b: Nivolumab+Binimetinib	Percentage of Participants With Complete Response as Per RECIST v1.1	0 Percentage of participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Percentage of Participants With Complete Response as Per RECIST v1.1	0 Percentage of participants
Phase 2: Nivolumab+Binimetinib	Percentage of Participants With Complete Response as Per RECIST v1.1	0 Percentage of participants
Phase 2: Nivolumab+Ipilimumab+Binimetinib	Percentage of Participants With Complete Response as Per RECIST v1.1	0 Percentage of participants

Secondary

Phase 1b: Objective Response Rate (ORR) Per RECIST v1.1

ORR was defined as the percentage of participants who achieved a BOR of CR or PR as determined by investigator per RECIST v1.1. As per RECIST v1.1, CR was defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR was defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.

Time frame: From start of the treatment until disease progression, death or initiation of new anticancer therapy, whichever occurred first (Phase 1b: maximum up to 9 months approximately)

Population: All participants who received at least 1 dose of any study treatment in Phase 1b.

Arm	Measure	Value (NUMBER)
Phase 1b: Nivolumab+Binimetinib	Phase 1b: Objective Response Rate (ORR) Per RECIST v1.1	0.0 Percentage of participants
Phase 1b: Nivolumab+Ipilimumab+Binimetinib	Phase 1b: Objective Response Rate (ORR) Per RECIST v1.1	0.0 Percentage of participants

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Intervention model description

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)

Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1

Concentration Versus Time Summary of Plasma Concentration of Binimetinib

Duration of Response (DOR) as Per RECIST v1.1

Number of Participants With Abnormal Hepatic Laboratory Values

Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Hematology and Coagulation

Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on CTCAE v4.03: Chemistry

Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Chemistry and Thyroid Function

Number of Participants With Shift From Baseline in Laboratory Parameter Values Based on Normal Range: Hematology and Coagulation

Number of Participants With Treatment-Emergent Adverse Events (TEAE) Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03

Percentage of Participants With Complete Response as Per RECIST v1.1

Phase 1b: Objective Response Rate (ORR) Per RECIST v1.1